Drew Moghanaki: Single fraction lung SBRT has become my go-to for medically inoperable stage I NSCLC

Drew Moghanaki shared a post on X about a paper by Gregory Videtic et al. published in PubMed.

“Ten-Year Experience in Implementing Single-Fraction Lung SBRT for Medically Inoperable Early-Stage Lung Cancer”

Authors: Gregory Videtic, Chandana Reddy, Neil Woody, Kevin Stephans

“Single fraction lung SBRT has become my go-to for medically inoperable stage I NSCLC. How about others?”

Source: Drew Moghanaki/X

Dr. Drew Moghanaki, a Professor and Chief of Thoracic Oncology at the Department of Radiation Oncology, UCLA. He holds the Stanley Iezman and Nancy Stark Endowed Chair in Thoracic Radiation Oncology Research at the same university.

He specializes in treating lung cancer and other thoracic malignancies, focusing on advanced radiation therapy techniques like stereotactic body radiation therapy (SBRT), magnetic resonance-guided radiation therapy (MRgRT), and intensity-modulated radiation therapy (IMRT).